Treatment of ankylosing spondylitis in patients refractory to TNF-inhibition: Are there alternatives?

Current Opinion in Rheumatology

Volumn 24, Issue 3, 2012, Pages 252-260

  Kiltz, Uta ^a   Heldmann, Frank ^a   Baraliakos, Xenofon ^a   Braun, Juergen ^a  

^a RHEUMAZENTRUM RUHRGEBIET   (Germany)

Author keywords

ankylosing spondylitis; antirheumatic drugs; antitumor necrosis factor therapy; axial spondyloarthritis; biological; nonsteroidal

Indexed keywords

ABATACEPT; APREMILAST; BISPHOSPHONIC ACID DERIVATIVE; PAMIDRONIC ACID; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE; SARILUMAB; SECUKINUMAB; TOCILIZUMAB;

ANKYLOSING SPONDYLITIS; ANTIINFLAMMATORY ACTIVITY; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG SAFETY; HUMAN; IMMUNOREGULATION; MULTICENTER STUDY (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME;

ANTIRHEUMATIC AGENTS; EVIDENCE-BASED MEDICINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; SPONDYLITIS, ANKYLOSING; TREATMENT FAILURE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84859255344     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0b013e3283524b82     Document Type: Review

References (60)

1. Braun J, Sieper J. Ankylosing spondylitis. Lancet 2007; 369:1379-1390. (Pubitemid 46590387)
2. Rudwaleit M, van der Heijde D, Landewé R, et al. The Development of Assessment of SpondyloArthritis international Society (ASAS) classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009; 68:777-783.
3. Braun J, Baraliakos X. Imaging of axial spondyloarthritis including ankylosing spondylitis. Ann Rheum Dis 2011; 70 (Suppl. 1):i97-i103.
4. Baraliakos X, Listing J, Rudwaleit M, et al. The relationship between inflammation and new bone formation in patients with ankylosing spondylitis. Arthritis Res Ther 2008; 10:R104.
5. Chiowchanwisawakit P, Lambert RG, Conner-Spady B, et al. Focal fat lesions at vertebral corners on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis. Arthritis Rheum 2011; 63:2215-2225.
6. Machado P, Landewe R, Lie E, et al. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis 2011; 70:47-53.
7. Visvanathan S, Wagner C, Marini JC, et al. Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab. Ann Rheum Dis 2008; 67:511-517. (Pubitemid 351498433)
8. Visvanathan S, van der Heijde D, Deodhar A, et al. Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis. Ann Rheum Dis 2009; 68:175-182.
9. Braun J, van den Berg R, Baraliakos X, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011; 70:896-904.
10. van der Heijde D, Sieper J, Maksymowych WP, et al. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis 2011; 70:905-908.
11. Braun J, Bollow M, Neure L, et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995; 38:499-505.
12. Bollow M, Fischer T, Reisshauer H, et al. Quantitative analyses of sacroiliacal biopsies in spondyloarthropathies: T cells and macrophages predominate in early and active sacroiliitis-cellulartity correlates with the degree of enhancement detected by magnetic resonance imaging. Ann Rheum Dis 2000; 59:135-140. (Pubitemid 30305612)
13. François RJ, Neure L, Sieper J, Braun J. Immunohistologic examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumor necrosis factor a in two early cases and transforming growth factor b in three later stages. Ann Rheum Dis 2006; 65:713-720. (Pubitemid 43799168)
14. Appel H, Kuhne M, Spiekermann S, et al. Immunohistologic analysis of zygoapophyseal joints in patients with ankylosing spondylitis. Arthritis Rheum 2006; 54:2845-2851. (Pubitemid 44497763)
15. Appel H, Maier R, Wu P, et al. Analysis of IL-17 + cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response. Arthritis Res Ther 2011; 13:R95.
16. Appel H, Ruiz-Heiland G, Listing J, et al. Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum 2009; 60:3257-3262.
17. Neidhart M, Baraliakos X, Seemayer C, et al. Expression of cathepsin K and MMP-1 indicate persistent osteodestructive activity in longstanding ankylosing spondylitis. Ann Rheum Dis 2009; 68:1334-1339.
18. McGarry F, Neilly J, Anderson N, et al. A polymorphism within the interleukin 1 receptor antagonist (IL-1Ra) gene is associated with ankylosing spondylitis. Rheumatol 2001; 40:1359-1364.
19. Bal U, Unlu E, Bahar G, et al. Comparison of serum IL-1 beta, sIL-2R, IL-6, and TNF-alpha levels with disease activity parameters in ankylosing spondylitis. Clin Rheumatol 2007; 26:211-215. (Pubitemid 46020247)
20. Shen H, Goodall JC, Hill Gaston JS. Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis. Arthritis Rheum 2009; 60:1647-1656.
21. Appel H, Heydrich R, Loddenkemper C, et al. In situ detection of IL-17 secreting cells in the bone marrow of facet joints obtained from patients with ankylosing spondylitis. Arthritis Rheum 2008; 58 (Suppl):S351.
22. Song IH, Heldmann F, Rudwaleit M, et al. Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study. Ann Rheum Dis 2011; 70:1108-1110.
23. Lekpa FK, Farrenq V, Canoi-Poitrine F, et al. Lack of efficacy of abatacept in a xial spondyloarthropathies refractory to tumor-necrosis-factor inhibition. Joint Bone Spine 2012; 79:47-50.
24. Haibel H, Rudwaleit M, Listing J, et al. Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. Ann Rheum Dis 2005; 64:296-298. (Pubitemid 40193630)
25. Tan AL, Marzo-Ortega H, O'Connor P, et al. Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic resonance imaging study. Ann Rheum Dis 2004; 63:1041-1045. (Pubitemid 39120352)
26. Pathan E, Abraham SM, Van-Rossen L, et al. Efficacy and safety of apremilast, an oral phosphodiesterase inhibitor in ankylosing spondylitis. Arthritis Rheum 2011; 63:S646.
27. Maksymowych WP, Jhangri GS, Fitzgerald AA, et al. A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis. Arthritis Rheum 2002; 46:766-773. (Pubitemid 34214258)
28. Santra G, Sarkar RN, Phaujdar S, et al. Assessment of the efficacy of pamidronate in ankylosing spondylitis: an open prospective trial. Singapore Med J 2010; 51:883-887.
29. Song IH, Heldmann F, Rudwaleit M, et al. Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed. Arthritis Rheum 2010; 62:1290-1297.
30. Nocturne G, Dougados M, Constantin A, et al. Rituximab in the spondyloarthropathies: data of eight patients followed up in the French Autoimmnity and Rituximab (AIR) registry. Ann Rheum Dis 2010; 69:471-472.
31. Rodriguez-Escalera C, Fernandez-Nebro A. The use of rituximab to ttreat a patient with ankylosing spondylitis and hepatitis B. Rheumatol 2008; 47:1732-1733.
32. Huang Y, Cheng F, Zhang X, et al. Marked reduction of sacroiliacal joint inflammation on magnetic resonance imaging in a patient with ankylosing spondylitis after rituximab treatment. J Rheumatol 2011; 38:2083-2084.
33. Wendling D, Augé B, Streit G, et al. Lack of short-term efficacy of rituximab upon symptoms of ankylosing spondylitis treated for an associated vasculitis. Joint Bone Spine 2008; 75:510-511.
34. Baeten D, Sieper J, Emery P, et al. The anti-IL-17A monoclonal antibody Secukinumab (AIN457) showed good safety and efficacy in the treatment of active ankylosing spondylitis. Ann Rheum Dis 2011; 70 (Suppl3):127.
35. Braun J, van der Horst-Bruinsma IE, Huang F, et al. Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial. Arthritis Rheum 2011; 63:1543-1551.
36. Song IH, Hermann K, Haibel H, et al. Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial. Ann Rheum Dis 2011; 70:590-596.
37. Song IH, Hermann KG, Haibel H, et al. Relationship between active inflammatory lesions in the spine and sacroiliac joints and new development of chronic lesions on whole-body MRI in early axial spondyloarthritis: results of the ESTHER trial at week 48. Ann Rheum Dis 2011; 70:1257-1263.
38. Huang F, Gu J, Zhao W, et al. One-year open-label trial of thalidomide in ankylosing spondylitis. Arthritis Rheum 2002; 47:249-254. (Pubitemid 34627691)
39. Wei JC, Chan TW, Lin HS, et al. Thalidomide for severe refractory ankylosing spondylitis: a 6-month open-label trial. J Rheumatol 2003; 30:2627-2631. (Pubitemid 37549341)
40. Dudler J, Aubry-Rozier B. Tocilizumab in axial spondyloarthropathies: about 18 cases. Ann Rheum Dis 2011; 70 (Suppl3):128.
41. Brulhart L, Nissen M, Chevallier P, et al. Tocilizumab in a patient with ankylosing spondylitis and Crohn's disease refractory to TNF antagonists. Joint Bone Spine 2010; 77:625-626.
42. Henes JC, Horger M, Guenaydin I, et al. Mixed response to tocilizumab for ankylosing spondylitis. Ann Rheum Dis 2010; 69:2217-2218.
43. Cohen JD, Ferreira R, Jorgensen C. Ankylosing spondylitis refractory to tumor necrosis factor blockade responds to tocilizumab. J Rheumatol 2011; 38:1527.
44. Shima Y, Tomita T, Ishii T, et al. Tocilizumab, a humanized antiinterleukin-6 receptor antibody, ameliorated clinical symptoms and MRI findings of a patient with ankylosing spondylitis. Mod Rheumatol 2011; 21:436-439.
45. Del Castillo Pinol N, Gossec L, Sparsa L, et al. Tocilizumab for treatment of refractory spondyloarthritis: report of 5 patients. Ann Rheum Dis 2011; 70(Suppl3):343.
46. Zou J, Zhang Y, Thiel A, et al. Predominat cellular immune response to the cartilage autoantigenic G1 aggrecan in ankylosing spondylitis and rheumatoid arthritis. Rheumatology 2003; 42:846-855. (Pubitemid 37220933)
47. Zhou H, Appel H, Rudwaleit M, et al. Analysis of the CD8 + T cell response to the G1 domain of agrecan in ankylosing spondylitis. Ann Rheum Dis 2005; 64:722-729. (Pubitemid 40559299)
48. Bennett AN, Tan AL, Coates LC, et al. Sustained response to anakinra in ankylosing spondylitis. Rheumatology (Oxford) 2008; 47:223-224. (Pubitemid 351168239)
49. McCann FE, Palfreeman AC, Andrews M, et al. Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis. Arthritis Res Ther 2010; 12:R107.
50. Schett G, Hu A, Stevens R. Oral apremilast is effective with and without concomitant methotrexate therapy in the treatment of subjects with active psoriatic arthritis. Arthritis Rheum 2011; 63:S307.
51. Stevenson PH, Stevenson JR. Cytotoxic and migration inhibitory effects of biphosphonates on macrophages. Calcif Tissue Int 1986; 38:227-233. (Pubitemid 16137016)
52. Haibel H, Brandt J, Rudwaleit M, et al. Treatment of active ankylosing spondylitis with pamidronate. Rheumatology (Oxford) 2003; 42:1018-1020. (Pubitemid 37220983)
53. Cairns AP, Wright SA, Taggart AJ, et al. An open study of pulse pamidronate treatment in severe ankylosing spondylitis, and its effect on biochemical markers of bone turnover. Ann Rheum Dis 2005; 64:338-339. (Pubitemid 40193647)
54. Malaviya AN, Kapoor S, Garg S, et al. A new strategy of drug treatment in NSAID-unresponsive ankylosing spondylitis: combination of pamidronate and methylprednisolone monthly intravenous infusions on the background of a combianiton of disease modifying drufs sulfaslazine and methotrexate. J Assoc Physicians India 2007; 55:193-197.
55. Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med 2009; 361:888-898.
56. Genovese M, van den Bosch F, Roberson S, et al. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis. Arthritis Rheum 2010; 62:929-939.
57. Baraliakos X, Braun J, Baeten D, et al. Interleukin-17A blockade with secukinumab reduces spinal inflammation in patient with ankylosing spondylitis as early as week 6, as detected by magnetic resonance imaging. Arthritis Rheum 2011; 63:S972.
58. Braun J, Zochling J, Baraliakos X, et al. Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial. Ann Rheum Dis 2006; 65:1147-1153. (Pubitemid 44277387)
59. Sampaio EP, Sarno EN, Galilly R, et al. Thalidomide selectively inhibits tumoor necrosis factor alpha production by stimulated human monocytes. J Exp Med 1991; 173:699-703.
60. Rose-John S, Waetzig GH, Scheller J, et al. The IL-6/sIL-6R complex: as a novel target for therapeutic approaches. Expert Opin Ther Target 2007; 11:613-624. (Pubitemid 46730080)